Page 19 - JCTR-9-4

AboEl-Azm et al. | Journal of Clinical and Translational Research 2023; 9(4): 222-235 235
Trittschuh EH, et al. Effects of Regular and Long-acting [24] Gale SA, Acar D, Daffner KR. Dementia. Am J Med
Insulin on Cognition and Alzheimer’s Disease Biomarkers: 2018;131:1161-9.
A Pilot Clinical Trial. J Alzheimers Dis 2017;57:1325-34. [25] Ito K, Hutmacher MM. Predicting the Time to Clinically
[15] Claxton A, Baker LD, Hanson A, Trittschuh EH, Worsening in Mild Cognitive Impairment Patients and its
Cholerton B, Morgan A, et al. Long-Acting Intranasal Utility in Clinical Trial Design by Modeling a Longitudinal
Insulin Detemir Improves Cognition for Adults with Mild Clinical Dementia Rating Sum of Boxes from the ADNI
Cognitive Impairment or Early-stage Alzheimer’s Disease Database. J Alzheimers Dis 2014;40:967-79.
Dementia. J Alzheimers Dis 2015;44:897-906. [26] Evans S, McRae-McKee K, Wong MM, Hadjichrysanthou C,
[16] Rosenbloom MH, Barclay TR, Pyle M, Owens BL, De Wolf F, Anderson R. The Importance of Endpoint
Cagan AB, Anderson CP, et al. A Single-dose Pilot Trial Selection: How Effective does a Drug Need to be for
of Intranasal Rapid-acting Insulin in Apolipoprotein E4 Success in a Clinical Trial of a Possible Alzheimer’s
Carriers with Mild-moderate Alzheimer’s Disease. CNS Disease Treatment? Eur J Epidemiol 2018;33:635-44.
Drugs 2014;28:1185-9. [27] Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R,
[17] Reger MA, Watson GS, Green PS, Wilkinson CW, Baker Squatrito S, et al. Insulin Analogues Differently Activate
LD, Cholerton B, et al. Intranasal Insulin Improves Insulin Receptor Isoforms and Post-receptor Signalling.
Cognition and Modulates Beta-amyloid in Early AD. Diabetologia 2010;53:1743-53.
Neurology 2008;70:440-8. [28] Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF,
[18] Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Greengard P, et al. Stimulation of Beta-amyloid Precursor
Fishel MA, et al. Intranasal Insulin Administration Dose- Protein Trafficking by Insulin Reduces Intraneuronal Beta-
dependently Modulates Verbal Memory and Plasma amyloid and Requires Mitogen-activated Protein Kinase
Amyloid-beta in Memory-impaired Older Adults. Signaling. J Neurosci 2001;21:2561-70.
J Alzheimers Dis 2008;13:323-31. [29] Lee CC, Kuo YM, Huang CC, Hsu KS. Insulin Rescues
[19] Reger MA, Watson GS, Frey WH 2 , Baker LD, Amyloid Beta-induced Impairment of Hippocampal Long-
nd
Cholerton B, Keeling ML, et al. Effects of Intranasal term Potentiation. Neurobiol Aging 2009;30:377-87.
Insulin on Cognition in Memory-impaired Older Adults: [30] De Felice FG, Vieira MN, Bomfim TR, Decker H,
Modulation by APOE Genotype. Neurobiol Aging Velasco PT, Lambert MP, et al. Protection of Synapses
2006;27:451-8. Against Alzheimer’s-linked Toxins: Insulin Signaling
[20] Kellar D, Register T, Lockhart SN, Aisen P, Prevents the Pathogenic Binding of Abeta Oligomers. Proc
Raman R, Rissman RA, et al. Intranasal Insulin Modulates Natl Acad Sci U S A 2009;106:1971-6.
Cerebrospinal Fluid Markers of Neuroinflammation in [31] Craft S, Peskind E, Schwartz MW, Schellenberg GD,
Mild Cognitive Impairment and Alzheimer’s Disease: Raskind M, Porte D Jr. Cerebrospinal Fluid and Plasma
A Randomized Trial. Sci Rep 2022;12:1346. Insulin Levels in Alzheimer’s Disease: Relationship to
[21] Prabakaran A, Agrawal M, Dethe MR, Ahmed H, Severity of Dementia and Apolipoprotein E Genotype.
Yadav A, Gupta U, et al. Nose-to-brain Drug Delivery Neurology 1998;50:164-8.
for the Treatment of Alzheimer’s Disease: Current [32] Lochhead JJ, Wolak DJ, Pizzo ME, Thorne RG. Rapid
Advancements and Challenges. Expert Opin Drug Deliv Transport within Cerebral Perivascular Spaces Underlies
2022;19:87-102. Widespread Tracer Distribution in the Brain After
[22] Anderson NH, Woodburn K. Old-age psychiatry. In: Intranasal Administration. J Cereb Blood Flow Metab
Companion to Psychiatric Studies. Amsterdam: Elsevier; 2015;35:371-81.
2010. p. 635-92. [33] Cao B, Rosenblat JD, Brietzke E, Park C, Lee Y,
[23] Chen YX, Liang N, Li XL, Yang SH, Wang YP, Shi NN. Musial N, et al. Comparative Efficacy and Acceptability
Diagnosis and Treatment for Mild Cognitive Impairment: of Antidiabetic Agents for Alzheimer’s Disease and Mild
A Systematic Review of Clinical Practice Guidelines and Cognitive Impairment: A Systematic Review and Network
Consensus Statements. Front Neurol 2021;12:719849. Meta-analysis. Diabetes Obes Metab 2018;20:2467-71.

Publisher’s note
AccScience Publishing remains neutral with regard to jurisdictional
claims in published maps and institutional affiliations.
DOI: http://dx.doi.org/10.18053/jctres.09.202304.23-00013